Immunic Inc
IMUX0.927USD
-0.004-0.44%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
83.61MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Immunic Inc Unternehmen
Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.
Unternehmensinformationen
BörsenkürzelIMUX
Name des UnternehmensImmunic Inc
IPO-datumApr 17, 2014
CEODr. Daniel Vitt, Ph.D.
Anzahl der mitarbeiter91
WertpapierartOrdinary Share
GeschäftsjahresendeApr 17
Addresse1200 Avenue Of The Americas
StadtNEW YORK
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl10036
Telefon13322559818
Websitehttps://imux.com/
BörsenkürzelIMUX
IPO-datumApr 17, 2014
CEODr. Daniel Vitt, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Daniel Vitt, Ph.D.
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
391.88K
+3.98%
Dr. Joerg Neermann, Ph.D.
Dr. Joerg Neermann, Ph.D.
Independent Director
Independent Director
200.00K
+100.00%
Mr. Glenn Whaley, CPA
Mr. Glenn Whaley, CPA
Chief Financial Officer
Chief Financial Officer
95.51K
+89.09%
Dr. Duane D. Nash, M.D.
Dr. Duane D. Nash, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
42.03K
+90.78%
Mr. Jason Tardio
Mr. Jason Tardio
President, Chief Operating Officer
President, Chief Operating Officer
12.51K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
--
--
Dr. Andreas Muehler, M.D.
Dr. Andreas Muehler, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Inderpal Singh
Mr. Inderpal Singh
General Counsel
General Counsel
--
--
Ms. Maria Toernsen
Ms. Maria Toernsen
Independent Director
Independent Director
--
--
Dr. Hella Kohlhof, Ph.D.
Dr. Hella Kohlhof, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Daniel Vitt, Ph.D.
Dr. Daniel Vitt, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
391.88K
+3.98%
Dr. Joerg Neermann, Ph.D.
Dr. Joerg Neermann, Ph.D.
Independent Director
Independent Director
200.00K
+100.00%
Mr. Glenn Whaley, CPA
Mr. Glenn Whaley, CPA
Chief Financial Officer
Chief Financial Officer
95.51K
+89.09%
Dr. Duane D. Nash, M.D.
Dr. Duane D. Nash, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
42.03K
+90.78%
Mr. Jason Tardio
Mr. Jason Tardio
President, Chief Operating Officer
President, Chief Operating Officer
12.51K
--
Ms. Simona Skerjanec, M.D.
Ms. Simona Skerjanec, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BVF Partners L.P.
9.29%
abrdn Inc.
8.60%
Soleus Capital Management, L.P.
7.61%
Avidity Partners Management LP
4.65%
The Vanguard Group, Inc.
4.10%
Other
65.74%
Aktionäre
Aktionäre
Anteil
BVF Partners L.P.
9.29%
abrdn Inc.
8.60%
Soleus Capital Management, L.P.
7.61%
Avidity Partners Management LP
4.65%
The Vanguard Group, Inc.
4.10%
Other
65.74%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
26.20%
Investment Advisor
13.30%
Investment Advisor/Hedge Fund
11.31%
Individual Investor
1.36%
Research Firm
1.05%
Pension Fund
0.06%
Other
46.74%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
135
51.29M
53.53%
-8.04M
2025Q1
143
43.91M
45.87%
-16.90M
2024Q4
141
54.47M
60.46%
-15.06M
2024Q3
152
61.42M
68.19%
-8.79M
2024Q2
169
63.34M
74.84%
-9.30M
2024Q1
202
64.86M
76.52%
-3.93M
2023Q4
199
22.30M
46.89%
-13.27M
2023Q3
205
25.26M
53.96%
-11.93M
2023Q2
209
27.09M
58.47%
-12.08M
2023Q1
208
31.66M
68.86%
-6.82M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BVF Partners L.P.
8.90M
9.29%
--
--
Mar 31, 2025
abrdn Inc.
1.06M
1.11%
+1.06M
--
Mar 31, 2025
Soleus Capital Management, L.P.
7.29M
7.61%
--
--
Mar 31, 2025
Avidity Partners Management LP
4.45M
4.65%
-3.51M
-44.09%
Mar 31, 2025
The Vanguard Group, Inc.
3.93M
4.1%
+7.79K
+0.20%
Mar 31, 2025
Focus Partners Wealth, LLC
2.58M
2.7%
+415.10K
+19.14%
Mar 31, 2025
Gratus Capital LLC
2.11M
2.2%
+56.86K
+2.77%
Jun 30, 2024
Omega Fund Management, LLC
1.79M
1.87%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
1.40M
1.46%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
976.15K
1.02%
+23.86K
+2.51%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0.02%
Invesco NASDAQ Future Gen 200 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Anteil0.02%
Invesco NASDAQ Future Gen 200 ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
